Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH001 + Toripalimab in Advanced Solid Tumors
NCT04357756Phase 1Completed
- Sponsor
- Eucure Biopharma
- Start
- Apr 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YH001 in solid tumor, sponsored by Eucure Biopharma. Primary endpoints: Number of participants with adverse events and serious adverse events at 1 year, Maximum tolerated dose at 21 days and 1 more. Started Apr 2020; status: completed.
02
Drugs
YH001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04357756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04357756.